BRAF V600E + MAP2K1 I111S
|
Melanoma
|
BRAF V600E + MAP2K1 I111S
|
Melanoma
|
vemurafenib Sensitive: C3 – Early Trials
|
vemurafenib Sensitive: C3 – Early Trials
|
BRAF V600E + MAP2K1 I111S
|
Melanoma
|
BRAF V600E + MAP2K1 I111S
|
Melanoma
|
dabrafenib Sensitive: C3 – Early Trials
|
dabrafenib Sensitive: C3 – Early Trials
|